Loading news...
Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.
Vertex Pharmaceuticals is downgraded to Hold ahead of Q4 earnings due to underwhelming growth from key new drugs. Journavx and Casgevy sales remain niche, raising doubts about their ability to drive the next growth phase already priced into consensus. 2026 sales guidance and Q4 Journavx performance are critical; failure to beat expectations may trigger downside risk.
Evaluate the expected performance of Vertex (VRTX) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Candriam S.C.A. lowered its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 1.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 174,567 shares of the pharmaceutical company's stock after selling 1,831 shares during the quarter. Candriam S.C.A.
Jones Financial Companies Lllp grew its stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 18.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,124 shares of the pharmaceutical company's stock after purchasing an additional 1,108 shares during the quarter.
The yield curve has steepened following President Trump's nomination of Kevin Warch as the next Fed chair. This could translate to higher inflation and market volatility.
Intuitive Surgical's recent dip is a good buying opportunity, considering its prospects. Vertex Pharmaceuticals' shares could jump this year as it advances its clinical programs.
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AGF Management Ltd. decreased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 54.2% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,735 shares of the pharmaceutical company's stock after selling 9,150 shares during the period. AGF Management
Mission Wealth Management LP cut its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 30.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,967 shares of the pharmaceutical company's stock after selling 1,742 shares during
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Atlantic Union Bankshares Corp raised its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 64.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,688 shares of the pharmaceutical company's stock after purchasing an additional 5,741 shares
Thrivent Financial for Lutherans reduced its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 11.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 78,270 shares of the pharmaceutical company's stock after selling 9,932 shares during the
WCM Investment Management LLC decreased its position in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 1.2% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,150,132 shares of the pharmaceutical company's stock after selling 13,538 shares during the quarter. WCM
SHANGHAI, Feb. 2, 2026 /PRNewswire/ -- WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) for an innovative trispecific T-cell Engager (TCE) for the treatment of B-cell mediated autoimmune diseases.
Principal Financial Group Inc. lowered its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 0.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 406,500 shares of the pharmaceutical company's stock after selling 3,305 shares during the period. Principal Financial
Vertex Pharmaceuticals (VRTX) reached $470.1 at the closing of the latest trading day, reflecting a -1.17% change compared to its last close.
Bank of New York Mellon Corp reduced its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 2.0% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,569,165 shares of the pharmaceutical company's stock after selling 31,308 shares during the period. Bank
Federated Hermes Inc. decreased its position in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 3.8% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 186,569 shares of the pharmaceutical company's stock after selling 7,390 shares during the period. Federated Hermes Inc. owned 0.07%